Immunotherapy
Cancer treatment that trains the patient's own immune system to attack tumors.
Coverage of Immunotherapy is holding steady : 17 signals on the latest tracked day, up 70% from its three-week baseline of 10, across 4 domains (unchanged from a week ago). That makes it the #11 most-covered of the 289 concerns we track.
What’s changed
7 of the last 7 tracked days ran above the three-week baseline — a sustained move, not a one-day spike.
- iPSC-derived polyvalent vaccines as ontogenetically informed immunogens toward overcoming immune refractoriness in microsatellite-stable colorectal cancer: An emerging frontier in cancer immunotherapy. · Mol Immunol · 2026-08-13
- Immunotherapy in Colorectal Cancer: Novel Perspectives and Next Steps. · Am J Clin Oncol · 2026-08-13
- Modeling Cancer Outcomes and Economic Impact of the Anti-PD-1/PD-L1 Immunotherapy in the Gulf: United Arab Emirates, Oman, and Kuwait. · Clin Drug Investig · 2026-08-12
- Barrier-matched, pharmacodynamic (PD)-gated immunotherapy development in MSS/pMMR colorectal cancer. · Crit Rev Oncol Hematol · 2026-08-11
- Foretinib triggers immunogenic cell death and enhances efficacy of anti-CD47 immunotherapy in colorectal cancer. · Neoplasia · 2026-08-01
- Durable responses to immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients with poor performance status · Clinical Colorectal Cancer · 2026-07-31
What the reporting says
It shows up alongside Colorectal Cancer (195), MSI-H (40), KRAS (17), ctDNA (15), Clinical Oncology (18), FDA (32), Abstract (29), AI (16).
Two steps out: Wang (through Colorectal Cancer, 55 shared stories on the weaker link); Zhang (through Colorectal Cancer, 49 shared stories on the weaker link); Braf (through Colorectal Cancer, 47 shared stories on the weaker link); Chen (through Colorectal Cancer, 43 shared stories on the weaker link).
Tracked since Dec 31, with coverage on 101 separate days — concentrated in Oncology and Pubmed Targeted.